WilmerHale Represents ZebiAI Therapeutics in Acquisition by Relay Therapeutics
- 4.16.2021
On April 16, 2021, ZebiAI Therapeutics, Inc., an artificial intelligence company that pioneers the application of machine learning to massive datasets to enable drug discovery, and Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that they have entered into a definitive merger agreement pursuant to which Relay would acquire ZebiAI for $85 million of upfront payments, composed of $20 million in cash and $65 million in Relay common stock, plus up to an additional $185 million of contingent payments based on the achievement of certain platform- or program-related milestones, payable in Relay common stock, and a percentage of the proceeds of certain agreements entered into by Relay, payable in cash.
WilmerHale is representing ZebiAI in the deal, with a team led by Chris Barnstable-Brown, Ariel Soiffer and Jenna Ventorino, which also included Samantha Berkovits, Erin Anderson and Elijah Soko on corporate and M&A matters, and Scott Kilgore, Julie Hogan Rodgers and Meghan Walsh on employment, equity compensation and tax matters.
